Clinical Trial Update: Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn's Disease Who Have Previously Responded to Treatment With Sargramostim [Phase 3]

View source ↗

Summary

Phase 3 efficacy trial of sargramostim for retreatment of Crohn's disease patients who previously responded to sargramostim has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Crohn Disease | Phase 3 | Status: TERMINATED